Back to
Goldman Sachs Group Inc.
RNAC
Showing 6 of 7 quarters
Position history for
Goldman Sachs Group Inc.'s holdings in Cartesian Therapeutics, Inc.
Yes. Goldman Sachs holds 51,529 shares of RNAC (Cartesian Therapeutics), worth $371,524, as of its Q3 2026 13F filing. It reduced the position by 29,043 shares (-36.0%) from Q2 2026. Goldman Sachs has held RNAC since Q1 2026, across 3 quarterly 13F filings.
Current Value
$371,524
Current Shares
51,529
Total Value Change
-$121,449
Total Shares Change
—
Quarter-by-Quarter History
Other major holders of RNAC: FMR LLC, Squarepoint Ops LLC